Related Experiment Video
Updated: May 31, 2025
14:55
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
Published on: May 12, 2013
60.1K
Tofersen and other antisense oligonucleotides in ALS
Albert Ludolph1,2, Maximilian Wiesenfarth3
1Department of Neurology, Ulm University, Oberer Eselsberg 45, Ulm 89081, Germany.
Therapeutic Advances in Neurological Disorders
|January 23, 2025
Summary
Antisense oligonucleotide (ASO) therapy shows promise for treating neurodegenerative diseases like SOD1-amyotrophic lateral sclerosis (ALS). Tofersen, an ASO, demonstrated beneficial effects on biomarkers and functional outcomes in patients with SOD1-ALS.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Antisense oligonucleotide (ASO) therapies offer new hope for neurodegenerative disorders.
- Nusinersen has shown success in spinal muscular atrophy, a recessive disease.
- Superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) is a key target for dominant neurodegenerative diseases.
Purpose of the Study:
- To evaluate the efficacy of the ASO tofersen in treating SOD1-ALS.
- To understand the mechanistic effects of tofersen on biomarkers and functional outcomes.
- To explore potential improvements and unresolved questions regarding ASO therapy for SOD1-ALS.
Main Methods:
- Clinical trials involving tofersen treatment for SOD1-ALS patients.
- Monitoring of mechanistic and degenerative biomarkers.
- Assessment of functional outcomes, including weight stabilization and ALSFRS-R scores.
Main Results:
- Tofersen demonstrated a convincing beneficial effect in patients with SOD1-ALS.
- Preclinical studies in rodents accurately predicted the therapeutic effects in humans.
- Clinical efficacy correlated with sequential changes in biomarkers and functional improvements.
Conclusions:
- Tofersen shows significant therapeutic potential for SOD1-ALS, validating preclinical predictions.
- Further research is needed to elucidate the precise mechanisms of action and long-term effects.
- Investigating potential side effects, autoimmune responses, and preventative strategies is crucial for optimizing ASO therapy.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
02:30siRNA - Small Interfering RNAs
16.5K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.5K
01:24Parkinson's Disease: Treatment
198
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
198
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
653